Genmab A/S

Report azionario NasdaqGS:GMAB

Capitalizzazione di mercato: US$16.4b

Genmab Gestione

Criteri Gestione verificati 3/4

Genmab Il CEO è Jan G.J. de Winkel, nominato in Jun2010, e ha un mandato di 15.92 anni. la retribuzione annua totale è $ 10.70M, composta da 14% di stipendio e 86% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.07% delle azioni della società, per un valore di $ 176.69M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.2 anni e 8.2 anni.

Informazioni chiave

Jan G.J. de Winkel

Amministratore delegato

US$10.7m

Compenso totale

Percentuale dello stipendio del CEO14.02%
Mandato del CEO15.9yrs
Proprietà del CEO1.1%
Durata media del management6.2yrs
Durata media del Consiglio di amministrazione8.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Apr 09

Genmab: Multiple Binaries Could Alter The Thesis

Summary Genmab faces a pivotal transition as DARZALEX royalties end by 2029–2032, but multiple late-stage oncology catalysts could redefine its growth trajectory. Upcoming registrational readouts for EPKINLY, Rina-S, and petosemtamab in 2026–2027 could drive multi-billion-dollar peak sales and diversify GMAB’s revenue base. GMAB trades at a discounted 4x 2026 and 2.5x 2030 forward price-to-sales, despite strong double-digit revenue and EPS growth projections post-OpEx ramp. I maintain a 4/5 conviction rating, planning selective buying below $28.25 and profit-taking at $42, with risk tied to binary clinical outcomes. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Genmab's Outlook Beyond Darzalex's Patent Cliff

Summary Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company’s robust late-stage pipeline could offset DARZALEX revenue loss with new product launches expected between 2027-2031. Genmab’s strong balance sheet with $2.9 billion in cash and no long-term debt provides financial flexibility for R&D and strategic acquisitions. The current valuation aligns with a conservative scenario where all new product launches fail suggesting limited downside risk but strong upside potential. If Phase 3 trials succeed, Genmab could see massive growth in revenue and potentially double or triple its market value, making it a low-risk, high-reward investment. Read the full article on Seeking Alpha
Seeking Alpha • Mar 14

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Summary Genmab's stock fell after J&J opted out of developing GEN3014 due to its undifferentiated efficacy and worse safety and tolerability compared to Darzalex. Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Concerns about GEN3014's safety may have impacted investors' perceptions of Genmab’s HexaBody platform. Genmab has only one early-stage HexaBody candidate in the clinic. Focus should now shift to quarterly results and upcoming clinical data updates, starting with proof-of-concept results for Rina-S in endometrial cancer and updated phase 2 results for acasunlimab. Read the full article on Seeking Alpha
Seeking Alpha • Dec 08

Genmab Is Too Attractive To Ignore

Summary Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily by Darzalex and Kesimpta. Despite some setbacks and market concerns, Genmab's long-term growth prospects remain strong, supported by growing Epkinly revenues, expanding clinical pipeline and the acquisition of ProfoundBio. Continued strong topline growth, increasing cash flows, renewed margin expansion and pipeline maturation should drive a share price recovery in 2025 and beyond. Read the full article on Seeking Alpha
Seeking Alpha • Nov 06

Genmab: Looking To Manage My Position Around Q3 Earnings

Summary Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The company's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS, potentially reversing the recent 20% share price drop. Investors should watch for updates on Genmab’s pipeline, OpEx, and DARZALEX royalty trends, as well as the impact of the ProfoundBio acquisition. Despite risks, including competition and regulatory challenges, I maintain a strong conviction in GMAB, planning to add shares if positive earnings trigger a price move above $24. Read the full article on Seeking Alpha
Seeking Alpha • Aug 23

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Summary Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year. Operating margin pressure continues, acquisition of ProfoundBio extends the time to recovery by several quarters. Continued commercial and pipeline progress and the eventual return of margin expansion position Genmab well for long-term value creation. Read the full article on Seeking Alpha
Seeking Alpha • May 01

Genmab: A Complicated Tale

Summary Genmab's stock has lost over 35% of its value since December 2022 due to unfavorable arbitration cases and high spending on launching Epkinly. The company's top line is currently dominated by royalties from Darzalex, but it hopes Epkinly will contribute significantly to its revenue. Genmab has a strong pipeline with eight revenue-generating medications, nine clinical programs, and nine royalty candidates in Phase 2 or later trials. The company also recently made an acquisition to bolster its pipeline with some ADC candidates. A full investment analysis around Genmab A/S stock is presented in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Genmab Acquires A Missing Piece For Its Pipeline

Summary Genmab will acquire ProfoundBio for $1.8 billion in cash. The acquisition adds an important antibody drug conjugate ('ADC') platform, a missing piece in Genmab's platform. Genmab plans to advance ProfoundBio's lead candidate, Rina-S, to registrational trials with a potential approval as early as 2027. Rina-S has generated promising efficacy and safety in an early stage clinical trial in patients with ovarian and endometrial cancer. The ADC market is increasingly crowded, but an important market Genmab needs to expand into. Read the full article on Seeking Alpha
Seeking Alpha • Feb 21

Genmab: Recent Updates Support The Growth Narrative

Summary Genmab's 2023 annual report shows strong financial performance and continued clinical success, setting the company up for growth in 2024. The company's pipeline includes promising candidates and collaborations with industry giants, supporting future growth. Risks to consider include legal disputes and competition, but overall, Genmab's growth narrative remains intact. Read the full article on Seeking Alpha
Seeking Alpha • Jan 23

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Summary Genmab's appeal against Johnson & Johnson in an arbitration case has been denied, eliminating the potential upside for the company. Despite this setback, Genmab remains well positioned to create shareholder value through continued revenue growth and pipeline progression and expansion. The launch of Epkinly/Tepkinly and the growth of other products are expected to reduce Genmab's reliance on Darzalex royalties. The head-to-head phase 2 data of GEN3014 and Darzalex represent the most important clinical catalyst for Genmab this year. Read the full article on Seeking Alpha
Seeking Alpha • Jan 12

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Summary Genmab is a leading contender in the biotech industry with innovative technology, a robust pipeline, and strategic collaborations. Epcoritamab's growth is a positive trend to monitor, as it has shown impressive financial performance and secured regulatory approvals in multiple regions. DARZALEX, Genmab's flagship product, continues to be a substantial revenue driver, and investors should monitor its clinical programs for potential growth. Read the full article on Seeking Alpha
Seeking Alpha • Oct 18

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Genmab (GMAB) has announced Q3 worldwide net trade sales of $2.05B for Darzalex (daratumumab) anti-cancer monoclonal antibody medication, compared with $1.99B generated in Q2. Net trade sales were USD 1.09B in the U.S. and USD 955M in the rest of the world. Genmab (GMAB) receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to Johnson & Johnson (JNJ) subsidiary Janssen Biotech to develop, manufacture and commercialize daratumumab.
Seeking Alpha • Aug 08

Genmab improves FY 2022 guidance

Genmab (GMAB) improves FY 2022 guidance expects its 2022 revenue to be in the range of DKK 12,000M – 13,000M, an increase to the previous guidance of DKK 11,000M – 12,000M, driven primarily by the continued strong growth of DARZALEX net sales as well as the positive impact of the strong U.S. Dollar.  Such royalties are based on Genmab’s revised estimate of DARZALEX 2022 net sales of USD 7.8B – 8.2B compared to Genmab’s previous estimate of USD 7.5B – 8.0B. Anticipates its 2022 operating expenses to be in the range of DKK 7,600M – 8,200M, an increase to the previous guidance of DKK 7,200M – 7,800M, driven by increased investment related to pipeline progression and epcoritamab launch readiness activities as well as the negative impact of the strong U.S. Dollar. Operating profit to be in the range of DKK 3,800M – 5,400M, an increase to the previous guidance of DKK 3,200M – 4,800M.
Seeking Alpha • Jul 19

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Genmab (GMAB) said global net sales of Darzalex reported by Johnson & Johnson (JNJ) rose 38.6% to $1.99B in Q2. Net trade sales were USD 1.02B in the U.S. and $965M in the rest of the world. Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous formulations, under an license agreement with J&J unit Janssen Biotech. Shares are up 2.84% premarket.
Seeking Alpha • Jun 28

Genmab: A Royalty Powerhouse With A Strong Pipeline

Genmab is receiving substantial and growing royalties from big pharma partners. The royalties are helping the company build its pipeline and to establish its own commercial infrastructure. Epcoritamab could be Genmab's next blockbuster. The stock is not cheap but increasing investments should lead to increased profits in the long run.

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jan G.J. de Winkel rispetto agli utili di Genmab?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

US$821m

Dec 31 2025US$11mUS$2m

US$963m

Sep 30 2025n/an/a

US$2b

Jun 30 2025n/an/a

US$1b

Mar 31 2025n/an/a

US$1b

Dec 31 2024US$8mUS$1m

US$1b

Sep 30 2024n/an/a

US$702m

Jun 30 2024n/an/a

US$798m

Mar 31 2024n/an/a

US$791m

Jan 01 2024n/an/a

US$631m

Sep 30 2023n/an/a

US$590m

Jun 30 2023n/an/a

US$680m

Mar 31 2023n/an/a

US$757m

Dec 31 2022US$6mUS$1m

US$785m

Sep 30 2022n/an/a

US$745m

Jun 30 2022n/an/a

US$558m

Mar 31 2022n/an/a

US$354m

Dec 31 2021US$6mUS$1m

US$452m

Sep 30 2021n/an/a

US$448m

Jun 30 2021n/an/a

US$401m

Mar 31 2021n/an/a

US$880m

Dec 31 2020US$6mUS$1m

US$781m

Sep 30 2020n/an/a

US$889m

Jun 30 2020n/an/a

US$853m

Mar 31 2020n/an/a

US$349m

Dec 31 2019US$5mUS$1m

US$325m

Compensazione vs Mercato: La retribuzione totale di Jan G.J. ($USD 10.70M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 14.79M ).

Compensazione vs guadagni: La retribuzione di Jan G.J. è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Jan G.J. de Winkel (64 yo)

15.9yrs
Mandato
US$10,700,000
Compensazione

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Jan G.J. de Winkel
Co-Founder15.9yrsUS$10.70m1.07%
$ 176.7m
Anthony Pagano
Executive VP & CFO6.2yrsUS$4.70m0.017%
$ 2.8m
Rayne Waller
Executive VP & Chief Technical Operations Officer1.8yrsUS$2.70mNessun dato
Gregory David Mueller
Executive VPless than a yearUS$1.80mNessun dato
Christopher Cozic
Executive VP & Chief People Officer8.5yrsUS$3.40mNessun dato
Martine van Vugt
Executive VP & Chief Strategy Officer12.3yrsUS$2.40mNessun dato
Martin Schultz
Senior Directorno dataUS$300.00k0.0014%
$ 231.8k
Judith Klimovsky
Executive VP & Chief Development Officer9.3yrsUS$5.40m0.025%
$ 4.2m
Tahamtan Ahmadi
Executive VP5.2yrsUS$5.20m0.016%
$ 2.7m
Mijke Zachariasse
VP, Head of Antibody Research Materials & Directorno dataUS$300.00k0.0014%
$ 228.5k
Takahiro Hamatani
Senior Director of Finance Japan & Non-Independent Directorno dataUS$100.00k0.00013%
$ 21.4k
Brad Bailey
Executive VP & Chief Commercial Officer1.8yrsUS$2.10mNessun dato
6.2yrs
Durata media
53yo
Età media

Gestione esperta: Il team dirigenziale di GMAB è esperto e expertise (durata media dell'incarico 6.2 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Martin Schultz
Senior Director4.3yrsUS$300.00k0.0014%
$ 231.8k
Mijke Zachariasse
VP, Head of Antibody Research Materials & Director7.2yrsUS$300.00k0.0014%
$ 228.5k
Takahiro Hamatani
Senior Director of Finance Japan & Non-Independent Director4.3yrsUS$100.00k0.00013%
$ 21.4k
Michael Kavanagh
Senior Director1.3yrsUS$200.00k0.00086%
$ 141.4k
Anders Pedersen
Non-Independent Director22.5yrsUS$400.00k0.013%
$ 2.1m
Elizabeth O'Farrell
Independent Director4.2yrsUS$400.00k0.0031%
$ 504.6k
Deirdre Connelly
Independent Chairman of the Board9.2yrsUS$600.00k0.011%
$ 1.8m
Rolf Hoffmann
Independent Director9.2yrsUS$400.00k0.0062%
$ 1.0m
Pernille Erenbjerg
Independent Deputy Chairman11.3yrsUS$400.00k0.0089%
$ 1.5m
Paolo Paoletti
Independent Director11.3yrsUS$300.00k0.0041%
$ 670.6k
8.2yrs
Durata media
59.5yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GMAB sono considerati esperti (durata media dell'incarico 8.2 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/24 09:06
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Genmab A/S è coperta da 41 analisti. 22 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
James GordonBarclays
Xue ChenBarclays
Emily FieldBarclays